LEIDEN, The Netherlands, November 10 /PRNewswire/ -- OctoPlus N.V. , the recently listed drug delivery and development company, announces today that construction work to expand its facilities has begun. This expansion reflects the company’s strategic commitment to advance its product portfolio and grow its revenue-generating development services.
OctoPlus’ existing facilities comprise offices, laboratories and a GMP manufacturing plant that produces clinical-scale GMP batches for the development of OctoPlus’ own products and for its formulation development customers. The expansion is necessary to support clinical development for the company’s own products and to facilitate the growing demand for OctoPlus’ services. The new facilities will bring the current 2800 m2 building to a combined total of 6300 m2. The building will be located adjacent to OctoPlus’ headquarters in the Bio Science Park in Leiden.
The building will be built and owned by Fortress Participations B.V. who will lease it to OctoPlus. OctoPlus will invest in research equipment and GMP production equipment to operate the facilities. The company plans to move into the building towards the end of 2007.
Joost Holthuis, CEO of OctoPlus commented: “We are excited to see the start of construction of our new facilities. Our plans for expansion have been in place for some time and we are excited that construction work is now underway. This expansion will enable us to support the clinical development of our product pipeline and also further grow our revenue-generating service activities.”
About OctoPlus
OctoPlus N.V. is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products that are based on its proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics and other drugs.
OctoPlus is also a leading provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industry, with a focus on difficult to formulate active pharmaceutical ingredients in injectable formulations. The earnings and expertise that OctoPlus derives from rendering formulation and manufacturing services help to support its own drug development programs.
OctoPlus is listed on Euronext Amsterdam since October 4, 2006 under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus N.V. and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words “expect”, “anticipate”, “predict”, “estimate”, “project”, “plan”, “may”, “should”, “would”, “will”, “intend”, “believe” and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.
For further information, please contact: OctoPlus, Rianne Roukema, Corporate Communications, +31-71-524-4044
OctoPlus BV
CONTACT: For further information, please contact: OctoPlus, RianneRoukema, Corporate Communications, +31-71-524-4044
